Acerus Announces Waiver of Q4 Financial Covenant in Credit rating Agreement
3 min read
TORONTO–(Business enterprise WIRE)–Dec 24, 2020–
Acerus Prescribed drugs Corporation (“Acerus” or the “Company”) (TSX: ASP, OTCQB: ASPCF) now announced that it acquired a waiver letter from SWK Funding LLC (“SWK”) linked to the essential Minimal Earnings Covenant for Q4-2020 in its present credit score facility with Acerus.
All other phrases and problems in the SWK bank loan settlement continue being unchanged.
About Acerus
Acerus Prescribed drugs Company is a Canadian-primarily based specialty pharmaceutical firm concentrated on the commercialization and growth of innovative prescription products and solutions that boost individual practical experience, with a principal focus in the field of men’s well being. The Enterprise commercializes its products and solutions by means of its own salesforce in the United States and Canada, and through a international network of licensed distributors in other territories.
Acerus’ shares trade on TSX below the symbol ASP and on OTCQB less than the image ASPCF. For a lot more information and facts, pay a visit to www.aceruspharma.com and comply with us on Twitter and LinkedIn.
See With regards to Ahead-On the lookout Statements
Info in this press release that is not existing or historic factual info could represent forward searching details in the indicating of securities rules. Implicit in this data are assumptions regarding our upcoming operational results. These assumptions, despite the fact that regarded sensible by the enterprise at the time of planning, may establish to be incorrect. Visitors are cautioned that real effectiveness of the organization is issue to a quantity of threats and uncertainties, together with with respect to the Company’s capacity to repay its debts and fulfill its money covenants, and could vary materially from what is presently envisioned as established out earlier mentioned. In specific, these assumptions incorporate but are not minimal to, the next: the COVID-19 pandemic will not affect our enterprise plan and that of our suppliers, the COVID-19 pandemic will not last a lot of months and well being treatment pros will be readily available to hear about our goods and to go on education and learning programs linked to them. For far more exhaustive information on these threats and uncertainties you should refer to our yearly information and facts variety dated March 3, 2020 which is obtainable at www.sedar.com. Forward-hunting info contained in this push launch is primarily based on our existing estimates, anticipations and projections, which we believe are fair as of the recent day. You ought to not spot undue significance on forward-seeking data and need to not depend on this facts as of any other day. Even though we could elect to, we are below no obligation and do not undertake to update this information and facts at any unique time, whether as a result of new info, foreseeable future activities or or else, apart from as expected by applicable securities law.
Watch resource variation on businesswire.com:https://www.businesswire.com/information/residence/20201224005016/en/
Get hold of: Business Call
[email protected] Trader Relations Call
Chris Witty
Acerus Investor Relations
(646) 438-9385
Search phrase: NORTH America CANADA
Industry Keyword: BIOTECHNOLOGY PHARMACEUTICAL Health and fitness
Resource: Acerus Prescription drugs Company
Copyright Business Wire 2020.
PUB: 12/24/2020 07:30 AM/DISC: 12/24/2020 07:30 AM
http://www.businesswire.com/news/residence/20201224005016/en
